TB R&D Weekly Update: T-Cell Surface Markers as Potential Biomarkers for TB Treatment

Henao-Tamayo M, Irwin SM, Shang S, Ordway D, Orme IM. T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis. Tuberculosis (Edinb). 2011 Apr 27. [Epub ahead of print]

In this week’s article, potential cellular biomarkers are explored in the mouse model with three potential markers: PD-1 (program death-1) and TIM-3 (T cell immunoglobulin mucin-3) on CD8 T cells and KIRG-1 (killer cell lectin-like receptor G1) on both CD4 and CD8 T cells. The search for validated biomarkers that can predict treatment success has been a difficult one. The focus of much of the research on biomarkers has been on serum markers, because of practical reasons and considerations of use in resource-limited settings. Henao-Tamayo, et al., took a different focus looking at markers on the surface of lung T cells. Key points from the article include:

  • Flow cytometry analysis was used to look at t-cell populations in the lungs of C57BL/6 mice infected with H37RV and untreated, infected with H37RV and treated with rifampicin and isoniazid, and uninfected.
  • In one set of experiments, the markers CD27, PD-1, and Tim-3 on CD8 cells were highly expressed in infected/untreated mice which was in contrast to the decrease in levels of expression with decrease in bacterial load in infected/treated mice. By the end of treatment, the infected/treated mice had expression levels of these markers similar to uninfected mice.
  • The authors looked at T cell activation marker KLRG-1 which is found on the surface of T cells. This marker was decreased in expression on both CD4 and CD8 T cells after treatment.
  • The results may not be reflected in T cells obtained from the blood but it is worth investigating in the authors’ opinion.

Additional TB R&D News:

Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through Efflux

Metabolite-enabled eradication of bacterial persisters by aminoglycosides

New Findings Reported from Georgia Institute of Technology Describe Advances in Microbial Drug Resistance

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...